title: [Recombinant factor VIIa (rFVIIa). Description of use in a cohort of critical patients and prognostic markers].
abstract: OBJECTIVE
  Describe and identify the factors associated with the survival of the patients who received treatment with rFVIIa in an Intensive Care Unit (ICU).
  
  
  METHODS
  Longitudinal, ambispective, observational, descriptive study in a series of clinical cases performed from July 20, 2004 to July 20, 2006.
  
  
  METHODS
  The study population included 16 hospitalized patients in the Intensive Medicine Department (ICU) of the Hospital Marqués de Valdecilla (Santander).
  
  
  METHODS
  Inclusion criteria were: Patients who required rFVIIa at some time of their stay in the ICU.
  
  
  RESULTS
  Hemodynamic improvement of the patients treated with rFVIIa in an ICU, within the first 3 hours of the infusion (evaluated by an increase of SBP > 20 mmHg and/or increase of DBP > 8 mmHg) was associated to greater survival.
  
  
  CONCLUSIONS
  The present series of cases, with the disadvantage of its heterogeneity and the limited number of patients, stresses the role of hemodynamic improvement as a differentiating factor between those patients who survive and those who do not.
authors.affiliation: Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander. jandro120475@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: González Castro
authors.forename: B
authors.initials: B
authors.lastname: Suberviola Cañas
authors.forename: E
authors.initials: E
authors.lastname: Miñambres
authors.forename: F
authors.initials: F
authors.lastname: Ortiz Melón
mesh_terms: D000328:Adult; D015331:Cohort Studies; D016638:Critical Illness; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa